Literature DB >> 22977614

Functional dose-volume histograms for predicting radiation pneumonitis in locally advanced non-small cell lung cancer treated with late-course accelerated hyperfractionated radiotherapy.

Dongqing Wang1, Baosheng Li, Zhongtang Wang, Jian Zhu, Hongfu Sun, Jian Zhang, Yong Yin.   

Abstract

The aim of this study was to determine whether functional dose-volume histograms (FDVHs) are valuable for predicting radiation pneumonitis (RP), and to identify whether FDVHs have advantages over conventional dose-volume histograms (DVHs) for the prediction of RP in patients with locally advanced non-small cell lung cancer (LANSCLC). Fifty-seven patients with LANSCLC undergoing functional image-guided late-course accelerated hyperfractionated radiotherapy were enrolled. The grade of RP was evaluated according to the Common Toxicity Criteria 3.0. To identify predictive factors of RP, the FDVHs, including the volume of the functional lung receiving 5 Gy (FV(5)) through 50 Gy (FV(50)), mean perfusion-weighted lung dose (MPWLD) and functional normal tissue complication probability (FNTCP), were analyzed and compared to their counterparts [total lung receiving 5 Gy (V(5)) through 50 Gy (V(50)), mean lung dose (MLD) and normal tissue complication probability (NTCP)] derived from conventional DVHs. Univariate analysis revealed that V(5)-V(40), MLD, NTCP and FV(5)-FV(50), MPWLD, FNTCP were all statistically significant relative to the development of RP (all p<0.05). Multivariate analysis showed that only MLD and FV(15) were associated with RP (p=0.001 and 0.044, respectively). Receiver operator characteristic curve anaysis indicated that almost all of the FDVHs had larger areas under the curve compared to the DVHs, although no statistically significant difference was observed (p-value ranged from 0.066 to 0.951). FDVHs are valuable for predicting RP with the predictive efficiency equivalent to or slightly advantageous over conventional DVHs. More homogeneous studies involving larger numbers of patients are required to further assess the value of FDVHs for predicting RP.

Entities:  

Year:  2011        PMID: 22977614      PMCID: PMC3440837          DOI: 10.3892/etm.2011.301

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  27 in total

1.  Quantification of radiation-induced regional lung injury with perfusion imaging.

Authors:  L B Marks; M T Munley; D P Spencer; G W Sherouse; G C Bentel; J Hoppenworth; M Chew; R J Jaszczak; R E Coleman; L R Prosnitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-05-01       Impact factor: 7.038

2.  Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer.

Authors:  Katrien De Jaeger; Yvette Seppenwoolde; Liesbeth J Boersma; Sara H Muller; Paul Baas; José S A Belderbos; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

3.  Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy.

Authors:  Ellen D Yorke; Andrew Jackson; Kenneth E Rosenzweig; Scott A Merrick; Dorota Gabrys; Ennapadam S Venkatraman; Chandra M Burman; Steven A Leibel; C Clifton Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

4.  Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction?

Authors:  M Fan; L B Marks; D Hollis; G G Bentel; M S Anscher; G Sibley; R E Coleman; R J Jaszczak; M T Munley
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

Review 5.  Estimation of normal tissue complication probabilities with three-dimensional technology.

Authors:  L B Marks; L R Prosnitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-02-01       Impact factor: 7.038

6.  Prospective assessment of dosimetric/physiologic-based models for predicting radiation pneumonitis.

Authors:  Zafer Kocak; Gerben R Borst; Jing Zeng; Sumin Zhou; Donna R Hollis; Junan Zhang; Elizabeth S Evans; Rodney J Folz; Terrence Wong; Daniel Kahn; Jose S A Belderbos; Joos V Lebesque; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-01       Impact factor: 7.038

7.  Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy.

Authors:  T Piotrowski; M Matecka-Nowak; P Milecki
Journal:  Neoplasma       Date:  2005       Impact factor: 2.575

8.  The role of three dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram.

Authors:  L B Marks; D P Spencer; G W Sherouse; G Bentel; R Clough; K Vann; R Jaszczak; R E Coleman; L R Prosnitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-08-30       Impact factor: 7.038

9.  A potential to reduce pulmonary toxicity: the use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer.

Authors:  Konstantin Lavrenkov; Judith A Christian; Mike Partridge; Elena Niotsikou; Gary Cook; Michelle Parker; James L Bedford; Michael Brada
Journal:  Radiother Oncol       Date:  2007-05-09       Impact factor: 6.280

10.  Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer.

Authors:  Yvette Seppenwoolde; Katrien De Jaeger; Liesbeth J Boersma; José S A Belderbos; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

View more
  4 in total

1.  Pre-Radiation Therapy Fluorine 18 Fluorodeoxyglucose PET Helps Identify Patients with Esophageal Cancer at High Risk for Radiation Pneumonitis.

Authors:  Richard Castillo; Ngoc Pham; Edward Castillo; Samantha Aso-Gonzalez; Sobiya Ansari; Brian Hobbs; Diana Palacio; Heath Skinner; Thomas M Guerrero
Journal:  Radiology       Date:  2015-01-13       Impact factor: 11.105

2.  Functional and biologic metrics for predicting radiation pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.

Authors:  Dongqing Wang; Jingyu Zhu; Jinbo Sun; Baosheng Li; Zhongtang Wang; Ling Wei; Yong Yin; Hongfu Sun; Zheng Fu; Xingguo Zhang; Zongwei Huo
Journal:  Clin Transl Oncol       Date:  2012-07-20       Impact factor: 3.405

3.  Modeling Patient-Specific Dose-Function Response for Enhanced Characterization of Personalized Functional Damage.

Authors:  Daniel Rocky Owen; Phillip S Boonstra; Benjamin L Viglianti; James M Balter; Matthew J Schipper; William C Jackson; Issam El Naqa; Shruti Jolly; Randall K Ten Haken; Feng-Ming Spring Kong; Martha M Matuszak
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-01       Impact factor: 7.038

4.  Reasonable Timing of Radiotherapy for Stage IV Non-Small-Cell Lung Cancer During Targeted Therapy Based on Tumour Volume Change.

Authors:  Qingsong Li; Na Liang; Xia Zhang; Yi Zhang; Weiwei Ouyang; Shengfa Su; Zhu Ma; Yinxiang Hu; Yichao Geng; Xiaxia Chen; Bing Lu
Journal:  Front Oncol       Date:  2021-09-23       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.